Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

American Thoracic Society (ATS) 2024 - 120th International Conference

May 17 - 22, 2024

FASENRA (benralizumab)
AIRSUPRA (albuterol/budesonide)
TEZSPIRE (tezepelumab)
PRECISION
NOVELTY
BREZTRI/TRIXEO
CHRONICLE

pdf

Safety of Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis During the Open-Label Extension Period of the Phase 3 MANDARA Study

pdf

Effect of Benralizumab Versus Mepolizumab on Reduction in Oral Glucocorticoid use in Patients With Eosinophilic Granulomatosis With Polyangiitis: Phase 3 MANDARA Study

pdf

Pulmonary Involvement and Persistent Pulmonary Damage in Eosinophilic Granulomatosis With Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

pdf

Systematic Literature Review of Real-World Outcomes of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis

pdf

The Effect of Benralizumab Versus Mepolizumab on the Depletion of Eosinophils in the Treatment of Eosinophilic Granulomatosis With Polyangiitis During the Phase 3 MANDARA Study

pdf

Albuterol-Budesonide as Needed in Treatment in Acute Airway Obstruction: Rationale and Design of the ALTA Study

pdf

Efficacy of As-Needed Albuterol–Budesonide by Baseline Blood Eosinophil Count in Patients ≥18 Years With Moderate-to-Severe Asthma

pdf

Comparative Burden of Disease Associated With Short-Acting Beta2-Agonist and Systemic Corticosteroid Exposures in US Children, Adolescents, and Adults With Asthma

pdf

A Bayesian Dynamic Borrowing Approach to Evaluate the Efficacy of Albuterol-Budesonide as Needed in Adolescents With Asthma: Design of the ACADIA Study

pdf

Reduced Mucus Plugging With Tezepelumab is Spatially Associated With Reduced air Trapping in a Broad Population of Patients With Moderate-to-Severe Asthma

pdf

Efficacy of Tezepelumab in Black or African American Patients: A Pooled Analysis of the PATHWAY and NAVIGATOR Studies

pdf

Clinical Responses to Tezepelumab in Patients With Severe, Uncontrolled Asthma and History of Nasal Polyps From the NAVIGATOR Study

pdf

Effect of Tezepelumab on Exercise Tolerance in Patients With Severe, Uncontrolled Asthma From the NAVIGATOR Study

pdf

Efficacy of Biologics for Reducing Exacerbations Requiring Hospitalizations or Emergency Room Visits in Patients With Moderate-to-Severe, Uncontrolled Asthma

pdf

A Phase 4, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Tezepelumab in Patients With Severe Asthma, Including Underrepresented Racial and Clinical Groups: Initial Baseline Demographics and Clinical Characteristics From the PASSAGE Study

pdf

Asthma Exacerbation Rates as a Function of Biomarker Levels 4 Weeks After Initiation of Tezepelumab Treatment: An Analysis of the NAVIGATOR Study

pdf

Patient Characteristics and Treatment Patterns With Tezepelumab in the United States: An Early Claims Data Study

pdf

Effect of Biologics on Biomarkers of Type 2 Inflammation in Asthma: A Review of the Literature

pdf

Tezepelumab in Adults With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety From the Phase 2a COURSE Study

pdf

Tezepelumab in Adults With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety From the Phase 2a COURSE Study [Oral]

pdf

The Asthma Impairment and Risk Questionnaire (AIRQ®) Predicts Exacerbation Risk in Patients With Mild-to-Moderate and Severe Disease

pdf

Development of the Pediatric Asthma Impairment and Risk Questionnaire (AIRQ®): A Qualitative Study

pdf

Implementing the Asthma Impairment and Risk Questionnaire (AIRQ®) and Asthma Checklist in Primary and Specialty Care Practices: Effects on Exacerbation Occurrence

pdf

Patient-Reported Worsenings of Their Asthma and/or COPD (NOVELTY)

pdf

Defining trajectories in health status with Chronic Airways Assessment Test (CAAT) in a real-life cohort of patients with asthma and/or COPD (NOVELTY)

pdf

Lung Exposure Bioequivalence With Budesonide/Glycopyrrolate/Formoterol Fumarate With the Potential Next Generation Propellant Hydrofluoroolefin-1234ze Versus Hydrofluoroalkane-134a in Healthy Adults: A Charcoal Block Study

pdf

In Silico Lung Deposition Profiles of Three Single-Inhaler Triple Therapy Combinations Assessed With Functional Respiratory Imaging (FRI) at a low Inspiratory Flow Rate

pdf

Frequent Productive Cough in COPD Patients Without Exacerbation History is Associated With Increased Risk of Exacerbations and a Treatment Benefit From Budesonide/Glycopyrrolate/Formoterol Fumarate: A Post hoc Analysis of KRONOS

pdf

Effect of Triple Inhaled Therapy With Budesonide/Glycopyrrolate/Formoterol Fumarate on Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post-hoc Analysis of ETHOS

html

Cost-Effectiveness of Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) Versus Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) to Treat COPD Based on Mortality Risk Reduction From a Matching-Adjusted Indirect Treatment Comparison

pdf

Geographic and Payer Variation in the Prevalence, Demographics, and COPD-Related Hospital Utilization of Patients With COPD

pdf

Healthcare Utilization Burden, Treatment Patterns, and Cardiopulmonary Outcomes in Patients Following Hospital Discharge for a COPD Exacerbation in a United States Administrative Database

pdf

Increased Risk of Mortality for COPD Patients Associated With Initiation of Treatment With Multiple Inhaler Triple Therapy Versus Single Inhaler (Budesonide/Glycopyrrolate/Formoterol) in the United States: The MAZI Study

pdf

Association Between Severe Cardiovascular Events and Time Following Exacerbations of COPD: Meta-Analyses of EXACOS-CV Observational Studies From 8 Countries

pdf

Greater Exacerbation Reductions with Earlier Biologic Initiation After Severe Asthma Onset: Results from the CHRONICLE Study

pdf

Potential Explanatory Factors for Racial Disparities in Asthma Exacerbation Rates: Results from the CHRONICLE Study of US Specialist-Treated Patients with Severe Asthma

pdf

Mortality Among US Adults with Severe Asthma is Increased with Maintenance Systemic Corticosteroid Treatment: Results from the CHRONICLE Study

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização